Starting July 1, a new Medicare bridge program provides access to GLP-1 weight loss drugs for a $50 monthly copay. While this change increases accessibility for millions of beneficiaries, older adults face distinct health considerations that require close medical oversight.
Geriatric experts emphasize that these medications, which include Wegovy and Zepbound, may interact with other common prescriptions. Because these drugs slow stomach emptying, they can alter how the body absorbs medications for blood pressure, thyroid conditions, and diabetes. Doctors often need to adjust dosages to prevent complications like dizziness or dangerous fluctuations in blood sugar levels.
Beyond drug interactions, there are physical risks specific to those aged 50 and older. Weight loss often leads to a decrease in both muscle and bone mass, heightening the risk of fractures and osteoporosis. Furthermore, these drugs can dampen natural thirst cues, increasing the danger of dehydration. Given that dehydration often causes confusion and instability, the risk of falls becomes a significant concern for seniors.
Patients taking these medications should prepare for potential digestive side effects, including nausea, vomiting, and constipation. Medical guidance suggests eating smaller meals and avoiding spicy foods to manage these issues. It is important to remember that the new $50 copay applies to the bridge program and does not count toward standard Medicare Part D out-of-pocket spending caps.
Medical professionals recommend consistent monitoring during the initial phase of treatment. Patients should expect follow-up appointments every four to eight weeks to track weight loss, nutritional intake, and potential side effects. Always consult your primary physician or a specialist before starting any new prescription regimen to ensure safety and long-term health stability.